Cart
sales@molnova.com
Isoxaflutole
CAS No. 141112-29-0
Isoxaflutole( Merlin | RP 201772 | RP-201772 | RP201772 )
Catalog No. M27318 CAS No. 141112-29-0
Isoxaflutole is a low toxic herbicide and has been marketed as a substitute for atrazine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 104 | In Stock |
|
| 50MG | 158 | In Stock |
|
| 100MG | 227 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIsoxaflutole
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsoxaflutole is a low toxic herbicide and has been marketed as a substitute for atrazine.
-
DescriptionIsoxaflutole is a low toxic herbicide and has been marketed as a substitute for atrazine.
-
In Vitro——
-
In Vivo——
-
SynonymsMerlin | RP 201772 | RP-201772 | RP201772
-
PathwayOthers
-
TargetOther Targets
-
RecptorP450|PARP|IL Receptor|PDE4|PDE2A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number141112-29-0
-
Formula Weight359.32
-
Molecular FormulaC15H12F3NO4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCS(=O)(=O)c1cc(ccc1C(=O)c1cnoc1C1CC1)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Marrero MT, et al. Ayanin diacetate-induced cell death is amplified by TRAIL in human leukemia cells. Biochem Biophys Res Commun. 2012 Nov 9;428(1):116-20.
molnova catalog
related products
-
LOC14
LOC14 to be the most potent PDI inhibitor reported to date( EC50 : 500 nM).
-
Presatovir
Presatovir (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).Presatovir exhibits potent activity against a wide range of RSV A and B clinical isolates (mean EC50: 0.43 nM) [1]. GS-5806 inhibits pre to post triggered conformational changes of RSV F protein, suggesting a possible mechanism for antiviral activity.
-
Ruplizumab
Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
